Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23067
Full metadata record
DC FieldValueLanguage
dc.contributor.authorForbes, Josephine M-
dc.date.accessioned2020-04-28T23:20:02Z-
dc.date.available2020-04-28T23:20:02Z-
dc.date.issued2020-05-
dc.identifier.citationKidney International 2020; 97(5): 855-857-
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/23067-
dc.description.abstractDiabetes affects oxygen availability in the kidney, forcing the renal environment to rapidly and sustainably adapt. Physiological adaptations including activation of hypoxia inducible factor-1α and metabolic reprogramming toward pathways requiring less oxygen to maintain adenosine triphosphate production such as anaerobic glycolysis are impaired in the diabetic kidney. However, this study by Hasegawa et al. demonstrates renoprotection in diabetic kidney disease via the use of the hypoxia inducible factor-1α stabilizer enarodustat, opening a new therapeutic avenue to tackle these metabolic abnormalities.-
dc.language.isoeng-
dc.titleProlyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?-
dc.typeJournal Article-
dc.identifier.journaltitleKidney International-
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationMater Research Institute, The University of Queensland, TRI, Brisbane, Queensland, Australiaen
dc.identifier.affiliationFaculty of Medicine, The University of Queensland, St Lucia, Queensland, Australiaen
dc.identifier.doi10.1016/j.kint.2020.01.038-
dc.identifier.orcid0000-0002-5595-8174-
dc.identifier.pubmedid32331596-
dc.type.austinJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Jan 16, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.